Breaking the performance ceiling for neoantigen immunogenicity prediction
Nat Cancer
.
2023 Dec;4(12):1618-1621.
doi: 10.1038/s43018-023-00675-z.
Authors
Hugh O'Brien
1
,
Max Salm
2
,
Laura T Morton
1
,
Maciej Szukszto
3
,
Felix O'Farrell
1
,
Charlotte Boulton
3
,
Pablo D Becker
1
,
Yardena Samuels
4
,
Charles Swanton
5
,
Marc R Mansour
3
,
Sine Reker Hadrup
6
,
Sergio A Quezada
7
8
Affiliations
1
Achilles Therapeutics Ltd, London, UK.
2
Achilles Therapeutics Ltd, London, UK. m.salm@achillestx.com.
3
Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
4
Weizmann Institute of Science, Rehovot, Israel.
5
The Francis Crick Institute, London, UK.
6
Technical University of Denmark, Lyngby, Denmark. sirha@dtu.dk.
7
Achilles Therapeutics Ltd, London, UK. s.quezada@ucl.ac.uk.
8
Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK. s.quezada@ucl.ac.uk.
PMID:
38102360
DOI:
10.1038/s43018-023-00675-z
No abstract available
MeSH terms
Antigens, Neoplasm* / genetics
Humans
Substances
Antigens, Neoplasm
Grants and funding
20265/CRUK_/Cancer Research UK/United Kingdom
25253/CRUK_/Cancer Research UK/United Kingdom
24956/CRUK_/Cancer Research UK/United Kingdom
20466/CRUK_/Cancer Research UK/United Kingdom
17786/CRUK_/Cancer Research UK/United Kingdom
30025/CRUK_/Cancer Research UK/United Kingdom